Technical Analysis for ENTA - Enanta Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade B 95.41 -4.26% -4.25
ENTA closed down 4.26 percent on Friday, March 22, 2019, on approximately normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Down
See historical ENTA trend table...

Date Alert Name Type % Chg
Mar 22 New Downtrend Bearish 0.00%
Mar 22 Golden Cross Bullish 0.00%
Mar 22 Stochastic Reached Oversold Weakness 0.00%
Mar 22 BB Squeeze Ended Range Expansion 0.00%
Mar 22 Below Lower BB Weakness 0.00%
Mar 22 Lower Bollinger Band Touch Weakness 0.00%
Mar 22 Oversold Stochastic Weakness 0.00%
Mar 21 Bollinger Band Squeeze Range Contraction -4.26%
Mar 21 Multiple of Ten Bearish Other -4.26%
Mar 21 BB Squeeze + Lower Band Touch Range Contraction -4.26%

Older signals for ENTA ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Enanta Pharmaceuticals, Inc., a biotechnology company, engages in the development of small molecule drugs for the infectious disease areas. Its product candidates include ABT-450, an inhibitor of NS3 protease that is in Phase III clinical trials for the treatment of hepatitis C virus (HCV) infection; EDP-239, an NS5A Inhibitor for HCV infection; EDP-546, a Cyclophilin inhibitor, which is in preclinical studies for HCV infection treatment; and Nucleotide Polymerase inhibitor for HCV infection. The company also develops EDP-788, an intravenous drug for the treatment of methicillin-resistant Staphylococcus aureus bacteria. It has collaboration and license agreements with Novartis Institutes for BioMedical Research, Inc. and Abbott Laboratories. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.
Chemistry Biotechnology Chemical Compounds Infection Infectious Disease Cyclopropanes Hepatitis C Pyrrolidines Hepatitis C Virus HCV Infection Ns3 Ns5a Viruses
Is ENTA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 1 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 127.77
52 Week Low 64.085
Average Volume 278,692
200-Day Moving Average 90.994
50-Day Moving Average 91.1576
20-Day Moving Average 101.19
10-Day Moving Average 100.713
Average True Range 4.248
ADX 35.53
+DI 19.8167
-DI 20.2961
Chandelier Exit (Long, 3 ATRs ) 94.056
Chandelier Exit (Short, 3 ATRs ) 107.794
Upper Bollinger Band 106.2917
Lower Bollinger Band 96.0883
Percent B (%b) -0.07
BandWidth 10.083407
MACD Line 1.7648
MACD Signal Line 3.0802
MACD Histogram -1.3153
Fundamentals Value
Market Cap 1.82 Billion
Num Shares 19.1 Million
EPS -1.08
Price-to-Earnings (P/E) Ratio -88.34
Price-to-Sales 23.12
Price-to-Book 3.52
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 102.55
Resistance 3 (R3) 103.22 101.52 101.36
Resistance 2 (R2) 101.52 99.70 101.18 100.96
Resistance 1 (R1) 98.46 98.57 97.61 97.79 100.57
Pivot Point 96.76 96.76 96.33 96.42 96.76
Support 1 (S1) 93.70 94.94 92.85 93.03 90.25
Support 2 (S2) 92.00 93.81 91.66 89.86
Support 3 (S3) 88.94 92.00 89.46
Support 4 (S4) 88.27